一项评估奥雷巴替尼治疗持续性或慢性原发性免疫性血小板减少症患者的2期试验显示出有前景的疗效和安全性。 - Suppr | 超能文献

相似文献

1

A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia.一项评估奥雷巴替尼治疗持续性或慢性原发性免疫性血小板减少症患者的2期试验显示出有前景的疗效和安全性。

Am J Hematol. 2024 Jul;99(7):1392-1395. doi: 10.1002/ajh.27303. Epub 2024 Mar 28.

2

Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma-a single-center retrospective study.奥布替尼联合利妥昔单抗和来那度胺治疗低KPS评分老年初诊原发性中枢神经系统淋巴瘤患者的有效性和安全性——一项单中心回顾性研究

Neurol Sci. 2024 Jun;45(6):2931-2934. doi: 10.1007/s10072-024-07348-4. Epub 2024 Feb 7.

3

Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.三期临床试验（RERISE 研究）：雷替尼与伊马替尼治疗新诊断慢性期慢性髓性白血病的疗效和安全性比较结果。

Clin Cancer Res. 2017 Dec 1;23(23):7180-7188. doi: 10.1158/1078-0432.CCR-17-0957. Epub 2017 Sep 22.

4

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.达沙替尼在对BCR-ABL1酪氨酸激酶抑制剂耐药或不耐受的慢性期慢性髓性白血病患者中的疗效和安全性。

Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.

5

Development of dysplastic nevus during radotinib therapy in patients with chronic myeloid leukemia.

Indian J Dermatol Venereol Leprol. 2017 Nov-Dec;83(6):704-707. doi: 10.4103/ijdvl.IJDVL_1030_16.

6

Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.苏利替尼（HMPL-523），一种新型的 Syk 抑制剂，用于中国的原发性免疫性血小板减少症患者：一项随机、双盲、安慰剂对照、1b/2 期研究。

Lancet Haematol. 2023 Jun;10(6):e406-e418. doi: 10.1016/S2352-3026(23)00034-0. Epub 2023 Apr 4.

7

Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.艾曲泊帕治疗持续性和慢性免疫性血小板减少症儿童（PETIT）：一项随机、多中心、安慰剂对照研究。

Lancet Haematol. 2015 Aug;2(8):e315-25. doi: 10.1016/S2352-3026(15)00114-3. Epub 2015 Jul 28.

8

Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.将阿卡替尼（一种选择性的下一代布鲁顿酪氨酸激酶抑制剂）纳入治疗血液系统恶性肿瘤的临床实践。

Br J Haematol. 2021 Apr;193(1):15-25. doi: 10.1111/bjh.17184. Epub 2020 Nov 20.

9

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.在初治 CLL 患者中，阿卡替尼联合奥滨尤妥珠单抗与单用阿卡替尼和单用泽布替尼的间接比较。

Blood Adv. 2024 Jun 11;8(11):2861-2869. doi: 10.1182/bloodadvances.2023012142.

10

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.依鲁替尼治疗儿童慢性免疫性血小板减少症（PETIT2）的随机、多中心、安慰剂对照试验。

Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28.

引用本文的文献

1

From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy.从C481耐药规避到血小板保存：利扎布替尼重新定义免疫性血小板减少症的靶向治疗

Drug Des Devel Ther. 2025 Sep 11;19:8161-8180. doi: 10.2147/DDDT.S543620. eCollection 2025.

2

[Efficacy and safety of zanubrutinib in treating refractory/relapsed warm autoimmune hemolytic anemia].泽布替尼治疗难治性/复发性温抗体型自身免疫性溶血性贫血的疗效和安全性

Zhonghua Xue Ye Xue Za Zhi. 2025 Apr 14;46(4):355-358. doi: 10.3760/cma.j.cn121090-20241110-00442.

3

Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence.